These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 8306265

  • 1. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R, Blumenthal R, Sharkey RM, Goldenberg DM.
    Cancer; 1994 Feb 01; 73(3 Suppl):816-23. PubMed ID: 8306265
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
    Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.
    Nucl Med Biol; 1996 Jan 01; 23(1):1-8. PubMed ID: 9004907
    [Abstract] [Full Text] [Related]

  • 3. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ.
    Cancer Res; 1995 Jul 15; 55(14):3132-9. PubMed ID: 7606734
    [Abstract] [Full Text] [Related]

  • 4. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R, Chen S, Haim S, Goldenberg DM.
    Cancer; 1997 Dec 15; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [Abstract] [Full Text] [Related]

  • 5. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov 15; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 6. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
    Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM.
    Cancer Res; 1990 Apr 15; 50(8):2330-6. PubMed ID: 2180566
    [Abstract] [Full Text] [Related]

  • 7. The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice.
    Fujii T, Yamana H, Toh Y, Toh U, Fujita H, Shirouzu K, Morimatsu M.
    Surg Today; 1997 Apr 15; 27(11):1026-34. PubMed ID: 9413055
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF, Pinedo HM, Schlüper HM, Nijman HW, Boven E.
    Br J Cancer; 1992 May 15; 65(5):677-83. PubMed ID: 1586596
    [Abstract] [Full Text] [Related]

  • 9. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.
    Br J Cancer; 1996 Nov 15; 74(9):1397-405. PubMed ID: 8912535
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Carrel S, Bigner DD.
    Cancer Res; 1990 Mar 15; 50(6):1822-7. PubMed ID: 2407345
    [Abstract] [Full Text] [Related]

  • 11. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM.
    Cancer Res; 1992 Nov 01; 52(21):6036-44. PubMed ID: 1394228
    [Abstract] [Full Text] [Related]

  • 12. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W.
    Int J Cancer; 1998 Aug 31; 77(5):787-95. PubMed ID: 9688314
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W.
    Cancer Biother Radiopharm; 2004 Aug 31; 19(4):466-77. PubMed ID: 15453961
    [Abstract] [Full Text] [Related]

  • 14. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.
    Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM.
    Int J Cancer; 1997 Jul 29; 72(3):477-85. PubMed ID: 9247292
    [Abstract] [Full Text] [Related]

  • 15. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Cheng R, Kruper WJ, Fordyce W, Goeckeler W.
    Cancer; 1994 Feb 01; 73(3 Suppl):993-8. PubMed ID: 8306291
    [Abstract] [Full Text] [Related]

  • 16. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M, Quak JJ, Suh JS, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.
    Br J Cancer; 1991 Jan 01; 63(1):37-44. PubMed ID: 1989663
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine GM, Izon D, Gascon P.
    Cancer; 1994 Feb 01; 73(3 Suppl):864-77. PubMed ID: 8306272
    [Abstract] [Full Text] [Related]

  • 18. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.
    J Nucl Med; 2001 Jun 01; 42(6):967-74. PubMed ID: 11390564
    [Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
    Dadachova E, Bryan RA, Huang X, Ortiz G, Moadel T, Casadevall A.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
    [Abstract] [Full Text] [Related]

  • 20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.